Blood sucking parasites elaborate mechanisms to counteract the hemostatic system of their victim. Haemonchus contortus worms use several mechanisms directed against the normal platelet hemostatic function. Platelet adhesion onto collagen and fibrinogen, and the ristocetin-mediated interaction of von Willebrand Factor with glycoprotein (GP) Ib were inhibited by the protein extract of adult worms. Also platelet aggregation induced by collagen, thrombin, ADP, ristocetin or A23187 was inhibited. Although we obtained evidence for interference with fibrinogen binding to GPIIb/IIIa, the strongest inhibition was seen when the agonists collagen or thrombin were used. A small multisubunit inhibitor of collagen-induced platelet aggregation was partially purified using anion exchange chromatography, gelfiltration and RP-HPLC. The inhibitor has a pI between 4 and 6.5, elutes with a molecular weight of 23,800 Da after gelfiltration, and is part of the elaborate broad-spectrum antiplatelet activity that results in the potent synergistic anti-hemostatic cocktail produced by H. contortus.
Introduction
The Trichostrongylid nematode Haemonchus contortus, a parasite causing great economical losses in sheep herds, weakens and even kills its host by its blood feeding behavior (1) . Only the L4 larvae and adults of H. contortus suck blood from the mucosa of the abomasum, to which they are attached. They have evolved highly effective strategies to facilitate the acquisition of host blood, which is considered to be the parasite's main source of nutrients. Among the trichostrongyles, H. contortus is distinguished by its blood sucking ability due to, at least in part, a prominent buccal tooth presumed to function as a lancet for slitting blood vessels (2) . Research on H. contortus is mainly focussed on the prevention and immunological control (3) (4) (5) (6) (7) , and treatment (8) (9) (10) of the infection, and hence not much is known about the feeding behavior of the parasite. Haemonchus protease proteins have been most studied till now (11) (12) (13) . Greene et al. (14) studied the effect of H. contortus extracts on coagulation of ovine plasma. They found that a worm extract did not have inhibitory effects on coagulation, in contrast to the effects reported for other hematophagous parasites (15, 16 ).
An attempt to characterize the molecular entities responsible for impaired hemostasis has already been made for several hematophagous invertebrates such as ticks (17, 18) , leeches (19) (20) (21) (22) and hookworms (23, 24) . The canine hookworm Ancylostoma caninum produces antiplatelet (25) as well as anticoagulant (26) proteins. We sought to determine whether H. contortus also had such properties and tried to purify one of these. From the present study, it is clear that H. contortus has evolved an effective strategy directed against the blood platelets, to manipulate the host's hemostatic system.
Materials and Methods

Materials
Human collagen type I, thrombin, adenosine diphosphate (ADP), phenylmethanesulfonyl fluoride (PMSF), ortho-phenylenediamine (OPD) and A23187 were purchased from Sigma (St. Louis, MO). Horm collagen (equine tendon) was from Nycomed Arzneimittel GmbH (Munich, Germany), and ristocetin from abp (London, UK). Fibrinogen was a gift from Dr. J. Harsfalvi (University of Debrecen, Hungary). rfGPIb␣ was produced by CHO cells and purified as described (27) . To prepare a plasma pool, blood of 25 healthy volunteers was withdrawn in 3.13% sodium citrate (9:1 v/v) and centrifuged 15 min at 1,300 g.
Soluble Worm Extract
Screening of the antihemostatic properties of Haemonchus contortus was performed with the extract of approximately 3 g frozen adult worms (a gift from Dr. Schallig, University of Utrecht, The Netherlands). The worms were grinded with a Potter S. (B. Braun Melsungen AG, Melsungen, Germany) and resuspended in 50 mM HEPES, pH 7.0. The homogenate was cleared by centrifugation and filtration.
Plasma and Platelet Preparation
For aggregation tests, platelet-rich plasma (PRP) was prepared from whole blood obtained by venipuncture from healthy volunteers into one-tenth volume 3.13% sodium citrate which was centrifuged at 200 g for 10 min. The PRP was adjusted with Ca 2+ -free Tyrode's buffer (137 mM NaCl, 2.7 mM KCl, 0.5 mM NaH 2 PO 4 , 12 mM NaHCO 3 , 1 mM MgCl 2 , 5.6 mM glucose) to a platelet count of 300,000/l, determined on a Cell-dyn1300 (Abbott, Louvain-La-Neuve, Belgium).
To prepare washed platelets, blood anticoagulated with acid-citrate-dextrose (ACD), pH 4.5 (8.5:1.5 v/v), was centrifuged at 200 g for 20 min and the PRP was spun at 950 g for 10 min. The platelet pellet was resuspended twice with PBS containing 10% ACD and finally suspended in Ernes buffer, pH 7.3.
Aggregation Studies
Platelet aggregation was followed in an Elvi 840 dual-channel aggregometer (Elvi Logos, Milano, Italy) in which 250 l diluted PRP was stirred at 1,000 rpm at 37°C. Two hundred l PRP (300,000 platelets/l) was incubated 
Platelet Adhesion to Fibrinogen and Human Collagen Type I
Microtitre plates (96 well, Greiner, Frickenhausen, Germany) were coated overnight at 4°C with 5 g/ml fibrinogen or 30 µg/ml human collagen type I, in PBS. Hundred l washed platelets (10 5 /l, final concentration) in Ernes buffer, with final concentrations of 5 mM MgCl 2 and 0.15% non-fat dry milk, Fig. 1 Inhibition of platelet aggregation by Haemonchus contortus proteins. Aggregation was induced by a threshold concentration of agonist after 10 min preincubation of PRP at 37°C with 120 g/ml H. contortus extract (black bars) or filtrate (grey bars). The results shown are expressed as percentage inhibition and are the mean ± SE (n = 3; a: n = 2; b: n = 1) Fig. 2 (A) Dose-dependent inhibition of vWF binding to rfGPIb␣ by H. contortus crude extract. Extract supplemented with 0.2 mM PMSF, 750 g/ml ristocetin, and 0.1% Tween-20 was preincubated for 30 min at room temperature with immobilized rfGPIb␣. Then, a plasma pool, diluted in the same buffer, was incubated for 1,5 h at 37°C, and bound vWF detected. VWF binding in the absence of extract was defined as 100%. (B) Dose-dependent inhibition of platelet adhesion to human collagen type I (q) and fibrinogen (❒) by H. contortus filtered extract. Washed platelets (10 5 /l, final concentration) were preincubated with extract at room temperature for 10 min, in the presence of 5 mM MgCl 2 and 0.15% non-fat dry milk. After incubation of this mixture on the collagen or fibrinogen coated plates for 1.5 h at room temperature, bound platelets were detected. Platelet binding in the absence of extract was defined as 100% The crude extract was separated on a Fractogel-EMD-TMAE + column, in 50 mM Tris, pH 8.1, at a flow rate of 2 ml/min. Elution was performed with a 30 min 0-0.5 M NaCl linear gradient, followed by a 30 min 0.5 M NaCl step and another 30 min 1 M NaCl step. The platelet aggregation inhibitory activity eluted at the peak noted as pool 2. (B) Gelfiltration of H. contortus platelet inhibitor. TMAE-pool 2 was fractionated into three peaks on a Sephacryl column, equilibrated with PBS and eluted at a flow rate of 1.5 ml/min. The inhibitor was located in the peak noted as pool C. (C) Concentration of the inhibitory activity by anion exchange chromatography. SEP-pool C was applied on the Fractogel-EMD-TMAE + column, equilibrated with 50 mM Tris, pH 8.5. Elution was performed for 30 min with a 0-0.75 M NaCl linear gradient at a flow rate of 2 ml/min. The inhibitor eluted in the front and the top of the peak noted as pool RP were preincubated with 50 mM HEPES buffer, pH 7, or worm extract, for 10 min at room temperature. Then, 90 l of these mixtures was incubated on the coated plates at room temperature for 1.5 h. After washing, bound platelets were lysed with 150 l 0.1 M sodium citrate, pH 5.4 containing 0.1% TritonX-100 and 5 mM p-nitrophenyl phosphate (Acros, Geel, Belgium). After 2 h at room temperature, the colorimetric reaction was stopped by the addition of 100 l 2 N NaOH and absorption was measured at 405 nm.
vWF: RiCof-ELISA
The vWF:RiCof-ELISA, developed in our lab (27) , was used to look for an inhibitor of the binding of von Willebrand Factor (vWF) to GPIb. A one over two dilution series of the extract, supplemented with 750 g/ml ristocetin and 0.1% Tween-20, in 50 mM Tris, pH 8.1, containing 0.1% Tween-20, 750 g/ml ristocetin and 0.2 mM PMSF, was preincubated with immobilized rfGPIb␣ for 30 min at room temperature, prior to addition of a constant amount of the plasma pool, finally 1/100 diluted, in TBS containing 0.1% Tween-20 and 750 g/ml ristocetin. Bound vWF was detected with polyclonal rabbit antihuman vWF antibodies labeled with horse radish peroxidase (anti-vWF-Ig-HRP, Dako, Glostrup, Denmark).
Thrombin Time (TT) Clotting Assay
Platelet poor plasma (PPP) was obtained by centrifuging PRP at 1,300 g for 15 min. Prewarmed PPP (200 l, 1 min at 37°C) was incubated at 37°C with 100 l 4 U/ml thrombin in HEPES, pH 7.0, and the time until fibrin formation was measured. To evaluate the anticoagulant properties of H. contortus proteins, extract or filtrate was preincubated at 37°C with PPP or with thrombin for 1 min.
Partial Purification of the Inhibitor
Approximately 20 g H. contortus worms were mixed in 125 ml 50 mM Tris, pH 8.1, containing 0.2 mM PMSF, with a Sorvall Mixer. The extract was clarified by centrifugation before loading on a Fractogel-EMD-TMAE + anion exchange column (13 ml, 2.6 ϫ 2.5 cm) (Merck, Darmstadt, Germany), equilibrated with 50 mM Tris, pH 8.1, and eluted with a NaCl gradient, at a flow rate of 2 ml/min. Sodium dodecyl polyacrylamide gelelectrophoresis (SDS-PAGE) was performed on the fractions with a 10-20% Tricine gel (Invitrogen, Groningen, The Netherlands) according to the manufacturers protocol. Peaks were pooled and tested for activity. A Superdex 75 HR 16/60 (Pharmacia, Uppsala, Sweden) was used to separate 3 ml of the active TMAE-pool 2. The column was equilibrated and eluted with PBS at a flow rate of 0.75 ml/min. Fractions were assayed for inhibition. SDS-PAGE and a gelfiltration calibration kit (Pharmacia) were used to determine the molecular weights of the elution peaks. In addition, gelfiltration of the remaining TMAE-pool 2 was performed on a Sephacryl HR-100 column (2.6 ϫ 90 cm) (Pharmacia) equilibrated and eluted with PBS, at a flow rate of 1.5 ml/min. The active SEP-pool C (fractions 52 to 62), was concentrated, using the Fractogel-EMD-TMAE + anion exchange column, with a 0-0.75 M NaCl linear gradient in 50 mM Tris, pH 8.5, after lowering the salt concentration by diluting 5 times in 50 mM Tris, pH 8.5. SDS-PAGE and isoelectric focussing with a pH 3-10 IEF gel (Invitrogen), was performed according to the manufacturers protocol, on fractions, desalted on a PD-10 column (Pharmacia). Further purification of inhibitory fractions was performed on a Novapak C18 column (Waters, Milford, MS), equilibrated with 5% acetonitrile, 0.1% trifluoro acetate (TFA) and eluted with a linear gradient of 5-75% acetonitrile, 0.1% TFA for 25 min at a flow rate of 1 ml/min. Five fractions were collected, lyophilized and redissolved in PBS for aggregation tests.
Results
Soluble Worm Extracts
Three gram H. contortus parasites were homogenized in 19 ml 50 mM HEPES, pH 7.0, and the extract was centrifuged. A fraction was filtered to remove residual insoluble material, resulting in a drop in protein concentration from 3.6 mg/ml to 3 mg/ml.
For purification of the platelet inhibitor, a large protein extract of 20 g frozen H. contortus worms was prepared in 125 ml 50 mM Tris, pH 8.1, containing 0.2 mM PMSF.
Inhibitory Activity of the Worm Extract
To assess the effect of the worm extract on platelet aggregability, PRP was preincubated at 37°C with 120 g/ml extract for 10 min. Platelet aggregation induced by collagen, thrombin or ADP, was completely inhibited whereas aggregation elicited by the Ca-ionophore A23187 was only partially impaired (Fig. 1) . After filtration, the extract lost some inhibitory activity. Four times higher amounts of filtrate were needed to obtain an inhibition of A23187-induced aggregation (not shown). Inhibition of collagen-and thrombin-induced aggregation was dose-dependent, with complete inhibition with 28.8 g/ml of extract protein.
The inhibition of ristocetin-induced platelet agglutination seen in Fig. 1 was confirmed by the vWF: RiCof ELISA, where preincubation of 0.5 mg/ml extract with rfGPIb␣, could completely inhibit the binding to vWF (Fig. 2A) . Preincubation of the extract with vWF gave exactly the same result.
To characterize the antiplatelet mechanism of the filtered extract more in detail, we tested its effect on platelet adhesion to collagen and fibrinogen, mediated by the platelet receptor GPIa/IIa and GPIIb/IIIa respectively. As shown in Fig. 2B , the filtrate inhibits both platelet interactions in a concentration-dependent manner. Adhesion of the platelets to fibrinogen could be nearly completely inhibited with 1,8 mg/ml filtrate, whereas the effect on the binding of platelets to collagen was limited to 30%.
Addition of high amounts of extract, filtered or not, significantly (P <0.05) but moderately prolonged the TT after incubation with PPP (Table 1 ). In contrast, preincubation of the extract with thrombin did not significantly affect the TT.
Partial Purification of the Inhibitor of Collagen-induced Platelet Aggregation
As collagen-induced platelet aggregation is strongly inhibited, we here concentrated our efforts to purify this inhibitory activity. As a high capacity column, a Fractogel-EMD-TMAE + anion exchange column was used to fractionate the large protein extract (Fig. 3A) . The first elution peak, eluting at 186 to 252 ml, formed TMAE-pool 2 (3.1 mg/ml) and contained the aggregation inhibitor.
A 3 ml sample of TMAE-pool 2 was further separated on an analytical Superdex 75 HR 16/60 column (Fig. 3B) . The two peaks with top fractions 80 and 101, eluted with an estimated molecular weight of 62,200 and 23,800 Da respectively. The inhibitory activity was located in the 101 peak. The remaining TMAE-pool 2 was loaded on a preparative Sephacryl HR-100 column (2.6 ϫ 90 cm) for further purification of the inhibitor. The elution pattern was the same with the Sephacryl HR-100 column as with the Superdex 75 HR 16/60 column. SEP-pool C (500 ml) containing the inhibitor, was concentrated on the Fractogel-EMD-TMAE + column (Fig. 3C) . Fractions 31 to 38 showed inhibitory activity, with a maximum in fraction 34. The eluted peak still contained a number of proteins with a pI between 4 and 6.5 (Fig. 4B ). Reduced fractions of the different columns were put on a Tris-Tricine gel (Fig. 4A) .
The pool of inhibitory fractions (pool RP) was finally separated by RP-HPLC in five fractions (Fig. 5 ), which were separately tested in collagen-induced aggregation. None of the individual fractions was however able to inhibit the aggregation, whereas the mix of the fractions restored the inhibitory activity (Fig. 6 ).
Discussion
For their blood meal, hematophagous parasites develop mechanisms to counteract the host hemostatic system. Several active proteins of different animals have already been identified (26, 28, 29) , providing an insight in the parasite's feeding mechanisms on the one hand and helping to unravel mechanisms of human hemostasis on the other hand (30) . Some proteins, such as hirudin from the leech Hirudo medicinalis, are nowadays used in human medicine (31) (32) (33) .
H. contortus elaborates a mechanism directed against amongst others the blood platelets, probably counteracting in this way the formation of a hemostatic plug, to ensure the free access to the blood stream. Platelet adhesion and aggregation, the first reactions in the formation of the plug as a consequence of injury to the blood vessels, are impaired by a series of products produced by the worm.
At the site of injury, platelets come in contact with the subendothelial collagen and bind to it with several platelet receptors. Amongs them, GPIa/IIa interacts in a direct manner via a Mg 2+ -dependent interaction that can be mimicked in a platelet adhesion test (21) and that is inhibited by the Haemonchus extract. In addition, the extract was able to inhibit collagen-induced aggregation, however, allowing platelet shape change to happen. Such inhibition pattern is typical for GPIa/IIa inhibition (34, 35) . Both tests let us to assume that a worm protein inhibits the binding of platelets to collagen via GPIa/IIa.
Attempts to purify the inhibitor of the collagen-platelet interaction were, due to the limited amounts of material, only partial. The inhibitory activity eluted in gelfiltration experiments with a molecular weight of around 23.8 kDa and had a pI between 4 and 6.5. It consists of several subunits that are separated by RP-HPLC, to result in inactive fractions which upon reconstitution, regain activity.
After activation of the platelets, fibrinogen binds to the GPIIb/IIIa receptor forming bridges between platelets, thus creating platelet aggregates (36) . Inhibition of this bridge formation results in inhibition of platelet aggregation induced by several agonists such as ADP, collagen and thrombin (37) . Each of these aggregations, however, also can be inhibited by impaired binding of the agonist itself to its platelet receptor. As A23187, in contrast, induces aggregation by a receptorindependent Ca 2+ -influx, inhibition of aggregation here is likely to be due to inhibition of fibrinogen binding to GP IIb/IIIa. The fibrinogenGPIIb/IIIa interaction was assayed in an ELISA test and was impaired by the protein extract. This, together with the inhibition of A23187-aggregations, strongly suggests the presence of an inhibitor acting on the GPIIb/IIIa-fibrinogen interaction. Whether the inhibitor binds to fibrinogen or to the receptor is at present not determined.
Ristocetin-induced vWF-dependent platelet agglutination, which is unaffected by a GPIIb/IIIa inhibitor (37) was also impaired, as was the RiCof-ELISA. Ristocetin, an antibiotic, induces GPIb-vWF binding under static conditions (38) . The results indicate the possible presence in the extract, of another inhibitor acting on the GPIb-vWF interaction.
The thrombin time was slightly increased by the extract, in contrast with the finding of Greene that the activated partial thromboplastin time (APTT) was shortened by the worm extract (14) , implying that there also might be an activator of coagulation steps leading to the thrombin generation. On the other hand, aggregation induced by a low thrombin concentration, was strongly inhibited, and thus presumably due to the presence of an inhibitor binding to a thrombin receptor, such as GPIb␣, (39, 40) , PAR1 (41, 41) , or PAR4 (43) .
Finally, the inhibition of ADP-induced aggregation seen with the extract, can be caused by the presence of either a P2Y1 antagonist (44) or a P2T antagonist (45) , or by inactivation of ADP itself e.g. by an apyrase (46, 47) .
It is clear from our studies that also H. contortus, like other hematophagous parasites, has developed an elaborate strategy to overcome the hemostatic systems of its host. We here could demonstrate a broadspectrum antiplatelet effect, which, when acting in concert, may well provide a potent synergistic cocktail. These results may provide new tools for the development of new antithrombotic agents for humans as well as lead products for the development of veterinary vaccins.
